Scotia Capital’s Zomedica Corp. ZOM Stock Holding History

Scotia Capital’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-47,477	Closed	-$16K	–	920
2022 Q1	$16K	Buy	+47,477	New	+$15.5K	﹤0.01%	870

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Scotia Capital's ZOM Position: Q2 2022 in Review

Scotia Capital sold out of Zomedica Corp. (ZOM) in Q2 2022, closing a stake of 47,477 shares — an estimated $16K sold.

Scotia Capital first reported a position in ZOM in Q1 2022 and held it in 1 quarter. The position peaked at $16K in Q1 2022. 97 funds tracked by Wall St. Rank hold ZOM as of Q2 2022.

Scotia Capital reported no remaining Zomedica Corp. position as of Q2 2022 after selling out during the quarter.
Scotia Capital sold 47,477 Zomedica Corp. shares in Q2 2022, an estimated $16K.
Scotia Capital first reported a position in Zomedica Corp. in Q1 2022 and held it in 1 quarter.
Scotia Capital's Zomedica Corp. position peaked at $16K in Q1 2022.
97 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2022.

Based on Scotia Capital's 13F filing for Q2 2022, filed 5 Aug 2022.